NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. is investigating potential claims against Stemline Therapeutics, Inc. (NASDAQ:STML) concerning possible violations of the federal securities laws.
On January 19, 2017, Stemline announced its proposed public offering. Then on February 2, 2017, TheStreet.com reported that a patient in a clinical trial of the Company's cancer drug SL-401 died from a severe side effect – the third death linked to the same SL-401 toxicity. This report indicated that one of the patient deaths occurred on January 18, 2017 and was not disclosed to investors who bought shares pursuant to the offering. Following this news, Stemline shares declined $4.15, or over 42.5%, per share on February 2, 2017.
If you purchased or otherwise acquired Stemline Therapeutics securities and suffered a loss, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact J. Brandon Walker, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Stemline Therapeutics, please go to www.bespc.com/stemline-therapeutics. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.
